Lose Weight with Science: Powerful Weekly Injections That Work
Weight loss injections curb appetite and boost fat loss. Popular options include Wegovy, Ozempic, Saxenda, and Mounjaro.
AVAILABLE TREATMENTS
Mounjaro (Tirzepatide Injections)
Mounjaro (Tirzepatide Injections)
Mounjaro (Tirzepatide Injections)
Mounjaro® (Tirzepatide) is a once-weekly injectable prescription medication used to improve blood sugar control in adults with type 2 diabetes mellitus. It is the first and only dual GIP and GLP-1 receptor agonist, offering a novel approach to diabetes management by enhancing insulin secretion, reducing glucagon levels, slowing gastric emptying, and promoting weight loss. Mounjaro is also being studied and used off-label for weight management, with significant results in body weight reduction.
Available Dosage Strengths:
2.5 mg – Starting dose (not for maintenance)
5 mg – First maintenance dose
7.5 mg – Titration dose
10 mg – Titration or maintenance dose
12.5 mg – Titration or maintenance dose
15 mg – Maximum maintenance dose
Ozempic (Semaglutide Injections)
Mounjaro (Tirzepatide Injections)
Mounjaro (Tirzepatide Injections)
Ozempic® (Semaglutide) is a once-weekly injectable GLP-1 receptor agonist used to improve glycemic control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and established heart disease. It works by enhancing insulin secretion, lowering glucagon secretion, slowing gastric emptying, and supporting weight loss.
Available Dosage Strengths:
0.25 mg – Starting dose (not for long-term use)
0.5 mg – Standard maintenance dose
1 mg – Higher maintenance dose
2 mg – Maximum dose for enhanced blood sugar control
Wegovy (Semaglutide Injections)
Mounjaro (Tirzepatide Injections)
Wegovy (Semaglutide Injections)
Wegovy® (Semaglutide) is a once-weekly injectable GLP-1 receptor agonist designed for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol. It works by mimicking the GLP-1 hormone to regulate appetite, increase satiety, and reduce calorie intake.Wegovy is administered subcutaneously and is supplied in a series of prefilled, single-dose pens to support gradual dose escalation, improving tolerance and minimizing gastrointestinal side effects.
Available Dosage Strengths:
0.25 mg – Initial starting dose (Weeks 1–4)
0.5 mg – Second step (Weeks 5–8)
1 mg – Third step (Weeks 9–12)
1.7 mg – Fourth step (Weeks 13–16)
2.4 mg – Maintenance dose (Week 17 and beyond)
Saxenda (Liraglutide)
Saxenda (Liraglutide)
Wegovy (Semaglutide Injections)
Saxenda® (Liraglutide) is a once-daily injectable prescription medication used for chronic weight management in adults with obesity or overweight (with related health risks), and in adolescents (ages 12–17) with obesity. It works by mimicking the GLP-1 hormone, helping regulate appetite and calorie intake to support long-term weight loss.Unlike diabetes-focused GLP-1 medications, Saxenda is specifically indicated for weight loss, not for blood sugar control.
Titration & Dosage Schedule:
Saxenda is supplied as a prefilled multi-dose pen (6 mg/mL). Treatment begins at a low dose and is gradually increased over 5 weeks to help minimize gastrointestinal side effects.
Weekly Dose Escalation:
Week 1: 0.6 mg
Week 2: 1.2 mg
Week 3: 1.8 mg
Week 4: 2.4 mg
Week 5 and beyond (maintenance): 3.0 mg
Plerixafor (Mozobil)
Saxenda (Liraglutide)
Victoza (Liraglutide)
Plerixafor (Mozobil®) is a hematopoietic stem cell mobilizer used in combination with granulocyte colony-stimulating factor (G-CSF) to enhance the release of stem cells into the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma.
Plerixafor works as a CXCR4 chemokine receptor antagonist, disrupting the interaction between CXCR4 and SDF-1α, which results in the rapid mobilization of hematopoietic stem cells from the bone marrow to peripheral blood.
Recommended dose: 0.24 mg/kg body weight
Maximum dose: 40 mg per day
Administered 6–11 hours prior to apheresis
Storage Conditions:
Store at 2°C to 8°C (36°F to 46°F)
Do not freeze
Protect from light
Single-use vial – discard unused portion
Victoza (Liraglutide)
Saxenda (Liraglutide)
Victoza (Liraglutide)
Victoza® (Liraglutide) is a once-daily, injectable GLP-1 receptor agonist used to improve blood sugar control in adults and children (10 years and older) with type 2 diabetes mellitus. It also reduces the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes and established cardiovascular disease. Victoza mimics the body’s natural GLP-1 hormone, enhancing insulin secretion, reducing glucagon release, slowing gastric emptying, and supporting modest weight loss.
Victoza is supplied as a multi-dose prefilled injection pen containing 6 mg/mL of liraglutide. The injection is given once daily, at any time of day, with or without food.
Doses per pen:
0.6 mg/day: up to 15 doses
1.2 mg/day: up to 7 doses
1.8 mg/day: up to 5 doses
Injection Sites: Abdomen, thigh, or upper arm
Formulation: Clear, colorless solution
Zepbound (Tirzepatide)
Trulicity (Dulaglutide)
Trulicity (Dulaglutide)
.jpg/:/cr=t:0%25,l:0%25,w:100%25,h:100%25/rs=w:388,h:388,cg:true)
Zepbound™ (Tirzepatide) is a once-weekly injectable prescription medication used for chronic weight management in adults with obesity or overweight who have at least one weight-related condition, such as hypertension, type 2 diabetes, or high cholesterol.Zepbound is a dual GIP and GLP-1 receptor agonist, working by mimicking natural gut hormones to reduce appetite, improve satiety, and lower caloric intake, supporting effective and sustainable weight loss.Zepbound contains the same active ingredient as Mounjaro, but it is specifically approved for weight management rather than type 2 diabetes.
Week 1–4: 2.5 mg
Week 5–8: 5 mg
Week 9–12: 7.5 mg
Week 13–16: 10 mg
Week 17–20: 12.5 mg (optional step)
Week 21 and beyond: 15 mg (maximum maintenance dose)
Trulicity (Dulaglutide)
Trulicity (Dulaglutide)
Trulicity (Dulaglutide)
Trulicity® (Dulaglutide) is a once-weekly injectable GLP-1 receptor agonist used to improve blood sugar control in adults and children (10 years and older) with type 2 diabetes mellitus. It is also approved to reduce the risk of major cardiovascular events (such as heart attack or stroke) in adults with type 2 diabetes and established cardiovascular disease.Trulicity helps lower blood glucose by stimulating insulin release, suppressing glucagon secretion, and slowing gastric emptying. It also supports modest weight loss.
Type 2 diabetes mellitus in adults and children (≥10 years)
Cardiovascular risk reduction in adults with type 2 diabetes and established CVD
Not for type 1 diabetes or diabetic ketoacidosis
Trulicity is administered once weekly, subcutaneously, and is available in multiple fixed-dose prefilled pens:
Available Dosages:
0.75 mg – Starting dose for most adults
1.5 mg – Standard maintenance dose
3.0 mg – For additional glycemic control if needed
4.5 mg – Maximum approved dose for enhanced control
Byetta (Exenatide)
Trulicity (Dulaglutide)
Byetta (Exenatide)
Byetta® (Exenatide) is a twice-daily GLP-1 receptor agonist used to improve blood sugar control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise. It helps regulate blood glucose levels by enhancing insulin secretion, suppressing glucagon, and slowing gastric emptying.
Byetta is not insulin and is not for use in patients with type 1 diabetes or diabetic ketoacidosis.
For adults with type 2 diabetes
May be used alone or with other oral diabetes medications
Dosage & Administration:
Form: Prefilled, multi-dose pen
Concentration: 250 mcg/mL
Starting Dose: 5 mcg twice daily (BID)
Inject within 60 minutes before morning and evening meals
After 1 month (if tolerated): Increase to 10 mcg BID for improved glycemic control
Maximum Dose: 10 mcg twice daily